| Old Articles: <Older 8091-8100 Newer> |
|---|
 |
The Motley Fool
November 30, 2011
Brian Orelli |
3 Things More Important to Pfizer Than Losing Lipitor It's not like we didn't see it coming.   |
The Motley Fool
November 29, 2011
Brian Orelli |
Winners and Losers of Roche's Avastin Woes What the FDA giveth, the FDA can taketh away. |
The Motley Fool
November 29, 2011
Brian Orelli |
Every Biotech Is for Sale It just depends on the right price. |
The Motley Fool
November 29, 2011
Rex Moore |
10 Great Values in Pharma and Biotech How to avoid the low-growth, high-risk value trap. |
The Motley Fool
November 29, 2011
Dan Caplinger |
Has Eli Lilly Become the Perfect Stock? The reason Lilly offers such an attractive yield and cheap valuation is that investors aren't sure it can keep up its past success. |
The Motley Fool
November 28, 2011
Brian Orelli |
Breaking Down a Biotech Press Release Aeterna Zentaris: FDA Grants IND to Investigator at Baylor College of Medicine for Phase 2A Trial with AEZS-130 in Cancer Cachexia. That sure is a mouthful. Let's see if we can break it down. |
The Motley Fool
November 28, 2011
David Williamson |
5 Biotechs Posting Big Gains The daily health-care news investors need to read. |
Pharmaceutical Executive
November 1, 2011 |
The Rx Club's 25th Anniversary Show Over 25 years the Rx Club Show has reflected dramatic technological changes in advertising. But, as always, the subject comes first, the medium second. So where did the accolades go this year? |
The Motley Fool
November 28, 2011 |
A Brief History of Amgen's Returns Amgen shares declined 17% over the past decade. What has happened? |
The Motley Fool
November 26, 2011
Stephanie Baum |
Pozen Inks $75 Million Royalty Deal for Treximet The pharma sells U.S. rights for the migraine drug to Canada's national pension fund. |
| <Older 8091-8100 Newer> Return to current articles. |
